share_log

On June 24, 2023, Bellerophon Therapeutics Approved Reduction-In-Force Of Substantially All Of Its Employees, Including Its Executive Officers - Filing

Benzinga ·  Jun 29, 2023 16:13

The determination to effect the workforce reduction was made in connection with the Company's decision to terminate its REBUILD Phase 3 clinical study of INOpulse for the treatment of fibrotic Interstitial Lung Disease ("fILD") and withdraw patients from the Company's ongoing INOpulse development programs.The Company intends to enter into separation and/or transition agreements with each of Peter Fernandes, the Company's Chief Executive Officer, Parag Shah, the Company's Vice President of Business Operations, and Martin Dekker, the Company's Vice President of Engineering and Manufacturing.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment